Commission Implementing Regulation (EU) 2021/1455 of 6 September 2021 approving the low-risk active substance Bacillus amyloliquefaciens strain AH2 in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending Commission Implementing Regulation (EU) No 540/2011 (Text with EEA relevance)

Approval of the active substance

Article 1

The active substance Bacillus amyloliquefaciens strain AH2, as specified in Annex I, is approved subject to the conditions laid down in that Annex.

Amendments to Implementing Regulation (EU) No 540/2011

Article 2

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with Annex II to this Regulation.

Entry into force

Article 3

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

ANNEX ISupplementary provisions

ANNEX I Common Name, Identification Numbers IUPAC Name Purity  ( 1 ) Date of approval Expiration of approval Specific provisions Bacillus amyloliquefaciens AH2 n.a. The nominal content of Bacillus amyloliquefaciens AH2 in the technical product and formulation is 1,0 × 10 11 CFU/L (range 7x10 10 – 7x10 11 ). No relevant impurities 27 September 2021 27 September 2036 For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on Bacillus amyloliquefaciens AH2 and in particular Appendices I and II thereof, shall be taken into account. ( 1 )   Further details on the identity and the specification of the active substance are provided in the renewal report.

ANNEX IISupplementary provisions

ANNEX II In Part D of the Annex to Implementing Regulation (EU) No 540/2011, the following entry is added: No. Common Name, Identification Numbers IUPAC Name Purity  ( 1 ) Date of approval Expiration of approval Specific provisions ‘33 Bacillus amyloliquefaciens AH2 n.a. The nominal content of Bacillus amyloliquefaciens AH2 in the technical product and formulation is 1,0 × 10 11 CFU/L (range 7x10 10 – 7x10 11 ). No relevant impurities 27 September 2021 27 September 2036 For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on Bacillus amyloliquefaciens AH2 and in particular Appendices I and II thereof, shall be taken into account. ( 1 )   Further details on the identity and the specification of the active substance are provided in the renewal report.’